Profile
Sophie Binay is currently the Deputy CEO & Chief Scientific Officer at Acticor Biotech SAS.
Previously, she worked as the Director of Nonclinical Research & Development at Minka Therapeutics SA, the VP of Research & Early Clinical Development at PEP-Therapy SAS, and the Head of Translational Programs at Gustave Roussy Institute.
Sophie Binay active positions
| Companies | Position | Start |
|---|---|---|
| ACTICOR BIOTECH SAS | Chief Tech/Sci/R&D Officer | 14/06/2021 |
Former positions of Sophie Binay
| Companies | Position | End |
|---|---|---|
Minka Therapeutics SA
 Minka Therapeutics SA Pharmaceuticals: MajorHealth Technology Minka Therapeutics SA develops therapeutic products and diagnostic complementary to current antiretroviral therapy in the treatment of AIDS. The firm provides therapeutic and diagnostic solutions for diseases linked to the immune system through its research on immune dysregulations. The company was founded by Patrice Debre, Vincent Vieillard, Michel Klein, Joël Crouzet, and Robert L. Murphy in 2008 and is headquartered in Evry, France. | Chief Tech/Sci/R&D Officer | - |
| Gustave Roussy Institute | Corporate Officer/Principal | - |
PEP-Therapy SAS
 PEP-Therapy SAS BiotechnologyHealth Technology PEP-Therapy SAS provides biotechnology development and research services. It engages in developing targeted therapies for the treatment of severe diseases, with an initial focus on cancer. The company was founded by Didier Decaudin, Fariba Némati, Angelita Rebollo and Antoine Prestat in January 2014 and is headquartered in Evry, France. | Chief Tech/Sci/R&D Officer | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ACTICOR BIOTECH SAS | Health Technology |
| Private companies | 3 |
|---|---|
Minka Therapeutics SA
Minka Therapeutics SA Pharmaceuticals: MajorHealth Technology Minka Therapeutics SA develops therapeutic products and diagnostic complementary to current antiretroviral therapy in the treatment of AIDS. The firm provides therapeutic and diagnostic solutions for diseases linked to the immune system through its research on immune dysregulations. The company was founded by Patrice Debre, Vincent Vieillard, Michel Klein, Joël Crouzet, and Robert L. Murphy in 2008 and is headquartered in Evry, France. | Health Technology |
PEP-Therapy SAS
PEP-Therapy SAS BiotechnologyHealth Technology PEP-Therapy SAS provides biotechnology development and research services. It engages in developing targeted therapies for the treatment of severe diseases, with an initial focus on cancer. The company was founded by Didier Decaudin, Fariba Némati, Angelita Rebollo and Antoine Prestat in January 2014 and is headquartered in Evry, France. | Health Technology |
| Gustave Roussy Institute |
- Stock Market
- Insiders
- Sophie Binay
